Kamada (NASDAQ:KMDA) Downgraded by Wall Street Zen to “Buy”

Kamada (NASDAQ:KMDA) was downgraded by research analysts at Wall Street Zen from a “strong-buy” rating to a “buy” rating in a report issued on Saturday.

Several other equities analysts also recently weighed in on KMDA. Stifel Nicolaus set a $11.00 target price on Kamada in a research report on Wednesday. Weiss Ratings reissued a “buy (b-)” rating on shares of Kamada in a research report on Thursday, January 22nd. HC Wainwright raised their price objective on shares of Kamada from $11.00 to $13.00 and gave the company a “buy” rating in a research note on Tuesday, December 9th. Finally, Benchmark restated a “buy” rating on shares of Kamada in a report on Thursday. Three equities research analysts have rated the stock with a Buy rating and one has given a Hold rating to the company. According to data from MarketBeat, Kamada presently has an average rating of “Moderate Buy” and a consensus price target of $13.00.

Kamada Stock Up 0.1%

KMDA opened at $8.70 on Friday. Kamada has a 52 week low of $5.54 and a 52 week high of $9.35. The business has a fifty day simple moving average of $8.44 and a 200-day simple moving average of $7.46. The firm has a market cap of $500.29 million, a P/E ratio of 24.86, a P/E/G ratio of 0.76 and a beta of 0.94.

Kamada (NASDAQ:KMDA) last issued its quarterly earnings data on Wednesday, March 11th. The biotechnology company reported $0.06 earnings per share for the quarter, missing analysts’ consensus estimates of $0.09 by ($0.03). The firm had revenue of $44.68 million during the quarter, compared to analyst estimates of $145.07 million. Kamada had a net margin of 11.19% and a return on equity of 7.80%. Sell-side analysts expect that Kamada will post 0.23 earnings per share for the current year.

Hedge Funds Weigh In On Kamada

Several hedge funds and other institutional investors have recently made changes to their positions in KMDA. Barclays PLC increased its stake in shares of Kamada by 417.1% during the fourth quarter. Barclays PLC now owns 4,788 shares of the biotechnology company’s stock worth $34,000 after buying an additional 3,862 shares during the period. China Universal Asset Management Co. Ltd. purchased a new position in Kamada in the fourth quarter worth approximately $66,000. Simplicity Wealth LLC purchased a new position in Kamada in the third quarter worth approximately $70,000. XTX Topco Ltd acquired a new position in Kamada during the 4th quarter worth approximately $103,000. Finally, SIH Partners LLLP purchased a new stake in shares of Kamada in the 4th quarter valued at approximately $134,000. Hedge funds and other institutional investors own 20.38% of the company’s stock.

Kamada Company Profile

Kamada Ltd. is a biopharmaceutical company headquartered in Israel that specializes in the development, manufacturing and commercialization of plasma‐derived protein therapeutics. The company focuses on treatments for rare and serious diseases, leveraging its proprietary fractionation and purification technologies to produce purified human proteins. Kamada’s product portfolio addresses critical therapeutic areas in immunology, hematology and pulmonology, where alternative treatment options may be limited.

Among Kamada’s marketed products is Glassia®, an alpha‐1 antitrypsin augmentation therapy approved by the U.S.